Hot-flash med could open up women's health category

Share this article:
Hot-flash med could open up women's health category
Hot-flash med could open up women's health category

Women seeking relief from hot flashes but wary of hormone replacement therapy got the promise of some relief when the FDA approved Noven Therapeutics' Brisdelle Friday. It is the first non-hormonal menopause medication to get the regulator's OK.

The FDA noted in the announcement that around 75% of menopausal women have hot flashes that can last up to, and even longer than, five years. Brisdelle won't make the discomfort go away, but it is indicated for reducing hot-flash severity.

This may seem like a fine line, but Friday's announcement opens up a therapeutic category shrouded by associated cancer risks. Unlike hormone-replacement therapy, which is generally an estrogen-progestin combination or an estrogen-only treatment, Brisdelle is the selective serotonin reuptake inhibitor (SSRI) paroxetine.

This SSRI is a component of medications that are used to treat conditions such as depression, obsessive compulsive disorder and post traumatic stress disorder, among others. Pair it with hydrochloride and you've got GlaxoSmithKline's Paxil. Tack on mesylate, and it's Noven's Pexeva.

Hormone-replacement therapy, or HRT, is a dicey category. Treatments had early promise of offering protection for the heart and lowering other cancer risks, but studies have found that the treatments can actually increase risks. Women taking HRT can up their risk for breast and ovarian cancer risk by around 50%, according to the American Cancer Society, which also notes that a government study found that estrogen-progestin therapy reduced the risk of colon cancer by around 40%.

The financial fallout of these findings has been mixed. Pfizer's SEC filings indicate the company has paid out around $1.6 billion in legal settlements, or 95% of personal-injury cases related to hormone replacement. Yet annual sales of its HRT franchise, which includes Premarin and Prempro, rose by 4% in 2012, to $1.2 billion, from $1.1 billion, and by 11% in 2011 vs. 2010.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.